Zacks Investment ResearchTue, 19 May 2026 19:30:54 GMTRegeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2BREGN-1.10%
Zacks Investment ResearchTue, 19 May 2026 16:56:07 GMTCan Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?REGN-1.10%
InvezzMon, 18 May 2026 19:25:19 GMTRegeneron stock drops double digits on oncology trial failureREGN-1.10%
Zacks Investment ResearchMon, 18 May 2026 19:17:19 GMTRegeneron's Late-Stage Melanoma Study Misses Primary GoalREGN-1.10%
Seeking AlphaMon, 18 May 2026 16:01:00 GMTRegeneron: Time To Forget Fianlimab (Rating Upgrade)REGN-1.10%
WSJMon, 18 May 2026 11:04:00 GMTRegeneron Shares Slide Premarket after Melanoma Drug Trial DisappointsREGN-1.10%
Seeking AlphaTue, 12 May 2026 20:11:17 GMTRegeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptREGN-1.10%
BenzingaThu, 30 Apr 2026 16:36:36 GMTRegeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 EarningsREGN-1.10%
Zacks Investment ResearchThu, 30 Apr 2026 14:40:30 GMTWhy Regeneron (REGN) is a Top Value Stock for the Long-TermREGN-1.10%
Seeking AlphaWed, 29 Apr 2026 18:01:35 GMTRegeneron Pharmaceuticals, Inc. (REGN) Q1 2026 Earnings Call TranscriptREGN-1.10%
BenzingaWed, 29 Apr 2026 17:57:11 GMTRegeneron Flags FDA Delays For Eylea HD Prefilled SyringeREGN-1.10%
Zacks Investment ResearchWed, 29 Apr 2026 17:31:12 GMTRegeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD StrengthREGN-1.10%
Zacks Investment ResearchWed, 29 Apr 2026 14:30:29 GMTRegeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to SayREGN-1.10%
Seeking AlphaWed, 29 Apr 2026 14:29:58 GMTRegeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD StrengthREGN-1.10%
Investors Business DailyWed, 29 Apr 2026 13:10:15 GMTRegeneron Slumps On An Unexpected Setback For Its Bread-And-Butter DrugREGN-1.10%
Zacks Investment ResearchWed, 29 Apr 2026 12:46:12 GMTRegeneron (REGN) Surpasses Q1 Earnings and Revenue EstimatesREGN-1.10%
Zacks Investment ResearchMon, 27 Apr 2026 17:11:33 GMTWill Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?REGN-1.10%
CNBCFri, 24 Apr 2026 18:37:03 GMTRegeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing lossREGN-1.10%
BenzingaFri, 24 Apr 2026 16:08:20 GMTRegeneron Strikes Deal With Trump Administration To Cut Drug PricesREGN-1.10%
